Logo Logo

Publications by Potenberg, Jochem

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 3.

Journal article

Chekerov, Radoslav; Hilpert, Felix; Mahner, Sven; El-Balat, Ahmed; Harter, Philipp; De Gregorio, Nikolaus; Fridrich, Claudius; Markmann, Susanne; Potenberg, Jochem; Lorenz, Ralf; Oskay-Oezcelik, Guelten; Schmidt, Marcus; Krabisch, Petra; Lück, Hans-Joachim; Richter, Rolf; Braicu, Elena Ioana; du Bois, Andreas; Sehouli, Jalid (2018): Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. In: Lancet Oncology, Vol. 19, No. 9: pp. 1247-1258

Gluz, Oleg; Nitz, Ulrike; Liedtke, Cornelia; Christgen, Matthias; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Bangemann, Nikola; Lindner, Christoph; Kuemmel, Sherko; Clemens, Michael; Potenberg, Jochem; Staib, Peter; Kohls, Andreas; Schumann, Raquel von; Harbeck, Nadia (2018): Comparison of Neoadjuvant Nab-Paclitaxe plus Carboplatin vs Nab-Paclitaxe plus Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. In: Jnci-Journal of the National Cancer Institute, Vol. 110, No. 6, djx258: pp. 628-637

Harbeck, Nadia; Gluz, Oleg; Christgen, Matthias; Kates, Ronald Ernest; Braun, Michäl; Küemmel, Sherko; Schumacher, Claudia; Potenberg, Jochem; Krämer, Stefan; Kleine-Tebbe, Anke; Augustin, Doris; Aktas, Bahriye; Forstbauer, Helmut; Tio, Joke; Schumann, Raquel von; Liedtke, Cornelia; Grischke, Eva-Maria; Schumacher, Johannes; Würstlein, Rachel; Kreipe, Hans Heinrich; Nitz, Ulrike Anneliese (2017): De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. In: Journal of Clinical Oncology, Vol. 35, No. 26: pp. 3046-3056

This list was generated on Mon Sep 23 06:59:37 2019 CEST.